The influence of melatonin receptors antagonists, luzindole and 4-phenyl-2-propionamidotetralin (4-P-PDOT), on melatonin-dependent vasopressin and adrenocorticotropic hormone (ACTH) release from the rat hypothalamo-hypophysial system. In vitro and in vivo studies

Journal of Physiology and Pharmacology

Volumn 65, Issue 6, 2014, Pages 777-784

  Juszczak, Marlena ^a   Roszczyk, M ^a   Kowalska, E ^a   Stempniak, B ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

4 phenyl 2 propionamidotetralin; Adrenocorticotropic hormone; Corticotrophin releasing hormone; Luzindole; Melatonin; Melatonin receptors; Vasopressin

Indexed keywords

4 PHENYL 2 PROPIONAMIDOTETRALIN; CORTICOSTERONE; CORTICOTROPIN; HORMONE RECEPTOR BLOCKING AGENT; LUZINDOLE; MELATONIN RECEPTOR; UNCLASSIFIED DRUG; VASOPRESSIN; 4-PHENYL-2-PROPIONAMIDOTETRALINE; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; TETRALIN DERIVATIVE; TRYPTAMINE DERIVATIVE; VASOPRESSIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HORMONAL REGULATION; HORMONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; NEUROHYPOPHYSIS; NONHUMAN; PHYSIOLOGY; QUANTITATIVE ASSAY; RADIOIMMUNOASSAY; RAT; STATISTICAL ANALYSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECTS; HYPOTHALAMUS HYPOPHYSIS SYSTEM; METABOLISM; WISTAR RAT;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; CORTICOSTERONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MELATONIN; RATS, WISTAR; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2; TETRAHYDRONAPHTHALENES; TRYPTAMINES; VASOPRESSINS;

EID: 84920008391     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Lemay A, Brouillette A, Denizeau F, Lavoie M. Melatoninand serotonin-stimulated release of vasopressin from rat neurohypophysis in vitro. Mol Cell Endocrinol 1979; 14: 157-166.
2. Juszczak M, Stempniak B, Guzek JW. Melatonin, pinealectomy and release of neurohypophysial hormones: in vitro studies. J Pineal Res 1992; 12: 1-6.
3. Roszczyk M, Juszczak M. Forskolin-stimulated vasopressin and oxytocin release from the rat hypothalamoneurohypophysial system in vitro is inhibited by melatonin. Endokrynol Pol 2014; 65: 125-131.
4. Yasin SA, Costa A, Besser GM, Hucks D, Grossman A, Forsling ML. Melatonin and its analogs inhibit the basal and stimulated release of hypothalamic vasopressin and oxytocin in vitro. Endocrinology 1993; 132: 1329-1336.
5. Juszczak M, Debeljuk L, Bartke A, Stempniak B. Melatonin inhibits oxytocin and vasopressin release from the neurointermediate lobe of the hamster pituitary. Neuroreport 1995; 6: 2453-2456.
6. Juszczak M, Boczek-Leszczyk E, Stempniak B. Effect of melatonin on the vasopressin secretion as influenced by tachykinin NK-1 receptor agonist and antagonist: in vivo and in vitro studies. J Physiol Pharmacol 2007; 58: 829-843.
7. Boczek-Leszczyk E, Stempniak B, Juszczak M. Vasopressin release from the rat hypothalamo-neurohypophysial system: effects of gonadotrophin-releasing hormone (GnRH), its analogues and melatonin. J Physiol Pharmacol 2010; 61: 459-466.
8. Forsling ML, Achaaban AR, Zhou Y. The effect of intracerebroventricular melatonin on vasopressin release in the conscious rat. J Endocrinol 1992; 135 (Suppl.): P47.
9. Bojanowska E, Forsling ML. The effect of melatonin on vasopressin secretion in vivo: interactions with acetylcholine and prostaglandins. Brain Res Bull 1997; 22: 457-461.
10. Mogulkoc R, Baltaci AK. Effect of melatonin supplementation on plasma vasopressin response to different conditions in rats with hyperthyroidism induced by Lthyroxine. Regul Pept 2010; 161: 38-42.
11. Boutin JA, Audinot V, Ferry G, Delagrange P. Molecular tools to study melatonin pathways and actions. Trends Pharmacol Sci 2005; 26: 412-419.
12. Dubocovich ML, Delagrange P, Krause DN, Sugden D, Cardinali DP, Olcese J. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev 2010; 62: 343-380.
13. Wiesenberg I, Missbach M, Carlberg C. The potential role of the transcription factor RZR/ROR as a mediator of nuclear melatonin signalling. Restr Neurol Neurosci 1998; 12: 143-150.
14. Morgan PJ, Barrett P, Howell HE, Helliwell R. Melatonin receptors: localization, molecular pharmacology and physiological significance. Neurochem Int 1994; 24: 101-146.
15. Dardente H, Klosen P, Pevet P, Masson-Pevet M. MT1 melatonin receptor mRNA expressing cells in pars tuberalis of the European hamster: effect of photoperiod. J Neuroendocrinol 2003; 15: 778-786.
16. Liu C, Weaver DR, Jin X, et al. Molecular dissection of two distinct actions of melatonin on the suprachiasmaticus circadian clock. Neuron 1997; 19: 91-102.
17. Vanecek J, Watanabe K. Mechanisms of melatonin action in the pituitary and SCN. Adv Exp Med Biol 1999; 460: 191-198.
18. Song CK, Bartness TJ, Petersen SL, Bittman EL. Coexpression of melatonin (MEL1a) receptor and arginine vasopressin mRNAs in the Siberian hamster suprachiasmatic nucleus. J Neuroendocrinol 2000; 12: 627-634.
19. Isobe Y, Torii T, Nishino H. Melatonin inhibits Argvasopressin release via MT(2) receptor in the suprachiasmatic nucleus-slice culture of rats. Brain Res 2001; 889: 214-219.
20. Ishii H, Tanaka N, Kobayashi M, Kato M, Sakuma Y. Gene structures, biochemical characterization and distribution of rat melatonin receptors. J Physiol Sci 2009; 59: 37-47.
21. Wu YH, Zhou JN, Balesar R, et al. Distribution of MT1 melatonin receptor immunoreactivity in the human hypothalamus and pituitary gland: colocalization of MT1 with vasopressin, oxytocin, and corticotrophin-releasing hormone. J Comp Neurol 2006; 499: 897-910.
22. Wu YH, Ursinus J, Zhou JN, et al. Alterations of melatonin receptors MT1 and MT2 in the hypothalamic suprachiasmatic nucleus during depression. J Affect Disord 2013; 148: 357-367.
23. Hermes ML, Coderre EM, Buijs RM, Renaud LP. GABA and glutamate mediate rapid neurotransmission from suprachiasmatic nucleus to hypothalamic paraventricular nucleus in rat. J Physiol 1996; 496: 749-757.
24. Cui LN, Saeb-Parsy K, Dyball RE. Neurones in the supraoptic nucleus of the rat are regulated by a projection from the suprachiasmatic nucleus. J Physiol 1997; 502: 149-159.
25. Sawchenko PE, Swanson LW, Vale WW. Corticotropinreleasing factor: coexpression within distinct subsets of oxytocin-, vasopressin- and neurotensin-immunoreactive neurons in the hypothalamus of the mate rat. J Neurosci 1984; 4: 1118-1129.
26. Bondy CA, Gainer H. Corticotropin-releasing hormone stimulates neurohypophysial hormone release through an interaction with the intermediate lobe of the pituitary. J Neuroendocrinol 1989; 1: 5-8.
27. Stratakis CA, Chrousos GP. Neuroendocrinology and pathophysiology of the stress system. Ann NY Acad Sci 1995; 771: 1-18.
28. Coiro V, Volpi R, Maffei ML, Volta E, Melani A, Chiodera P. Effect of naloxone on the inhibitory effect of melatonin on the release of arginine-vasopressin induced by physical exercise in man. Regul Pept 2010; 162: 1-4.
29. Juszczak M. Melatonin affects the oxytocin and prolactin responses to stress in male rats. J Physiol Pharmacol 1998; 49: 151-163.
30. Campino C, Valenzuela FJ, Torres-Farfan C, et al.Melatonin exerts direct inhibitory actions on ACTH responses in the human adrenal gland. Horm Metab Res 2011; 43: 337-342.
31. Tsukamoto N, Otsuka F, Ogura-Ochi K, et al. Melatonin receptor activation suppresses adrenocorticotropin production via BMP-4 action by pituitary AtT20 cells. Mol Cell Endocrinol 2013; 375: 1-9.
32. Richter HG, Torres-Farfan C, Garcia-Sesnich J, et al. Rhythmic expression of functional MT1 melatonin receptors in the rat adrenal gland. Endocrinology 2008; 149: 995-1003.
33. Gregg CM, Sladek CD. Acompartmentalized, organ-cultured hypothalamo-neurohypophysial system for the study of vasopressin release. Neuroendocrinology 1984; 38: 397-402.
34. Juszczak M. Neurokinin A and the neurohypophysial response to melatonin: in vitro studies. J Physiol Pharmacol 2002; 53: 823-834.
35. Noble EP, Wurtmen RJ, Axelrod J. A simple and rapid method for injecting H3-norepinephrine into lateral ventricle of the brain. Life Sci 1967; 6: 281-291.
36. Reiter RJ, Tan DX, Kim SJ, Cruz MH. Delivery of pineal melatonin to the brain and SCN: role of canaliculi, cerebrospinal fluid, tanycytes and Virchow-Robin perivascular spaces. Brain Struct Funct 2014; 219: 1873- 1887.
37. Yasin SA, Grossman A, Forsling ML. Diurnal variation in the effect of melatonin on neurohypophysial hormone release from the rat hypothalamus. Brain Res Bull 1996; 39: 1-5.
38. Zurowski D, Nowak L, Machowska A, Wordliczek J, Thor PJ. Exogenous melatonin abolishes mechanical allodynia but not thermal hyperalgesia in neuropathic pain. The role of the opioid system and benzodiazepine-gabaergic mechanism. J Physiol Pharmacol 2012; 63: 641-647.
39. Winczyk K, Fuss-Chmielewska J, Lawnicka H, Pawlikowski M, Karasek M. Luzindole but not 4-phenyl-2- propionamidotetralin (4P-PDOT) diminishes the inhibitory effect of melatonin on murine colon 38 cancer growth in vitro. Neuro Endocrinol Lett 2009; 30: 657-662.
40. Drobnik J, Tosik D, Piera L, et al. Melatonin-induced glycosaminoglycans augmentation In myocardium remote to infarction. J Physiol Pharmacol 2013; 64: 737-744.
41. Adamczyk-Sowa M, Sowa P, Zwirska-Korczala K, Pierzchala K. Labeled [3H] - thymidine incorporation in the DNA of 3T3-L1 preadipocytes due to MT2- and not MT3- melatonin receptor. J Physiol Pharmacol 2014; 65: 135-143.
42. Vitte PA, Harthe C, Lestage P, Claustrat B, Bobillier P. Plasma, cerebrospinal fluid, and brain distribution of 14Cmelatonin in rat: a biochemical and autoradiographic study. J Pineal Res 1988; 5: 437-453.
43. Vanecek J, Vollrath L. Melatonin inhibits cyclic AMP and cyclic GMP accumulation in the rat pituitary. Brain Res 1989; 505, 157-159.
44. MacKenzie RS, Melan MA, Passey DK, Witt-Enderby PA. Dual coupling of MT1 and MT2 melatonin receptors to cyclic AMP and phosphoinositide signal transduction cascades and their regulation following melatonin exposure. Biochem Pharmacol 2002; 63: 587-595.
45. Balik A, Kretschmannova K, Mazna P, Svobodova I, Zemkova H. Melatonin action in neonatal gonadotrops. Physiol Res 2004; 53 (Suppl. 1): S153-S166.
46. Benitez-King G, Huerto-Delgadillo L, Anton-Tay F. Melatonin modifies calmodulin cell levels in MDCK and N1E-115 cell lines and inhibits phosphodiesterase activity in vitro. Brain Res 1991; 557: 289-292.
47. Reiter RJ, Oh CS, Fujimori O. Melatonin: its intracellular and genomic actions. Trends Endocrinol Metab 1996; 7: 22-27.
48. Chowdrey HS, Lightman SL. Role of central amino acids and peptide-mediated pathways in neurohypophysial hormone release. Ann NY Acad Sci 1993; 689: 183-193.
49. Sladek CD, Kapoor JR. Neurotransmitter/neuropeptides interactions in the regulation of neurohypophysial hormone release. Exp Neurol 2001; 171: 200-209.
50. Sladek CD, Swenson KL, Kapoor R, Sidorowicz H. The role of steroid hormones in the regulation of vasopressin and oxytocin release and mRNA expression in hypothalamoneurohypophysial explants from the rat. Exp Physiol 2000; 858 (Spec. No): 171S-177S.
51. Yasin SA, Forsling ML. Mechanisms of melatonin inhibition of neurohypophysial hormone release from the rat hypothalamus in vitro. Brain Res Bull 1998; 45: 53-59.
52. Kusek M, Tokarski K, Hess G. Repeated restrained stress enhances glutamatergic transmission in the paraventricular nucleus of the rat hypothalamus. J Physiol Pharmacol 2013; 64: 565-570.
53. Chrousos GP. Stressors, stress, and neuroendocrine integration of the adaptive response: The 1997 Hans Selye memorial lecture. Ann NY Acad Sci 1998; 851: 311-335.
54. Konakchieva R, Mitev Y, Almeida OF, Patchev VK. Chronic melatonin treatment counteracts glucocorticoid-induced dysregulation of the hypothalamic-pituitary-adrenal axis in the rat. Neuroendocrinology 1998; 67: 171-180.
55. Otsuka T, Goto M, Kawai M, et al. Photoperiod regulates corticosterone rhythms by altered adrenal sensitivity via melatonin-independent mechanisms in Fischer 344 rats and C57BL/6J mice. PLoS One 2012; 7: e39090.